Mankind Pharma reports mixed half-year results, acquires women's health portfolio

Mankind Pharma Limited reported its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. For the six months ended September 30, 2025, consolidated revenue from operations increased to INR 7,267.51 crores, up from INR 5,929.28 crores in the prior year. Profit after tax for continuing operations for the period was INR 964.80 crores, compared to INR 1,199.73 crores for the same period last year. Total comprehensive income for the period stood at INR 986.95 crores, against INR 1,196.65 crores in the previous year.

On a standalone basis, the company’s revenue from operations for the six months ended September 30, 2025, reached INR 5,150.14 crores, an increase from INR 4,956.80 crores in the corresponding period of 2024. Standalone profit for the period from continuing operations was INR 871.66 crores, compared to INR 1,089.77 crores a year prior. Total standalone assets as of September 30, 2025, amounted to INR 24,861.82 crores.

The board of directors also approved the acquisition of Bharat Serums and Vaccines Limited’s Women's Health Portfolio for INR 797 crore, effective November 1, 2025. Additionally, the company granted 100,000 stock options and allotted 29,742 equity shares to eligible employees under the Mankind Employees Stock Option Plan 2022 during the period. The company also confirmed compliance with financial covenants related to its listed, rated, secured, redeemable, transferable non-convertible debentures.